{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T12:09:21Z","timestamp":1780056561666,"version":"3.54.0"},"reference-count":36,"publisher":"American Society for Microbiology","issue":"1","license":[{"start":{"date-parts":[[2022,1,18]],"date-time":"2022-01-18T00:00:00Z","timestamp":1642464000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2022,1,18]],"date-time":"2022-01-18T00:00:00Z","timestamp":1642464000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"DOI":"10.13039\/100010877","name":"ViiV Healthcare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010877","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2022,1,18]]},"abstract":"<jats:p>P1093 is a multicenter, open-label, phase I\/II study of pharmacokinetics, safety, and tolerability of dolutegravir plus an optimized background regimen in pediatric participants aged 4\u2009weeks to &lt;18\u2009years with HIV-1. Most participants were highly treatment experienced.<\/jats:p>","DOI":"10.1128\/aac.01645-21","type":"journal-article","created":{"date-parts":[[2021,10,25]],"date-time":"2021-10-25T18:50:23Z","timestamp":1635187823000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":32,"title":["Emergence of Resistance in HIV-1 Integrase with Dolutegravir Treatment in a Pediatric Population from the IMPAACT P1093 Study"],"prefix":"10.1128","volume":"66","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7179-3405","authenticated-orcid":true,"given":"Cindy","family":"Vavro","sequence":"first","affiliation":[{"name":"ViiV Healthcare, Research Triangle Park, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodore","family":"Ruel","sequence":"additional","affiliation":[{"name":"University of California San Francisco, San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Wiznia","sequence":"additional","affiliation":[{"name":"Jacobi Medical Center, Albert Einstein College of Medicine, Bronx, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Monta\u00f1ez","sequence":"additional","affiliation":[{"name":"FHI 360, Durham, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith","family":"Nangle","sequence":"additional","affiliation":[{"name":"Parexel International, Durham, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Horton","sequence":"additional","affiliation":[{"name":"Parexel International, Durham, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann M.","family":"Buchanan","sequence":"additional","affiliation":[{"name":"ViiV Healthcare, Research Triangle Park, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugene L.","family":"Stewart","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline, Upper Providence, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Palumbo","sequence":"additional","affiliation":[{"name":"Geisel School of Medicine at Dartmouth, Lebanon, New Hampshire, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","unstructured":"HHS Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV. Guidelines for the use of antiretroviral agents in pediatric HIV infection. https:\/\/clinicalinfo.hiv.gov\/sites\/default\/files\/guidelines\/documents\/PedARV_GL.pdf. Accessed 20 September 2020."},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2011-1740"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(18)30257-1"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)61221-0"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215541"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(13)70257-3"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.3851\/IMP3166"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkz256"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01643-21"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000000848"},{"key":"e_1_3_3_12_2","volume-title":"Tivicay package insert.","author":"ViiV Healthcare","year":"2021","unstructured":"ViiV Healthcare. 2021. Tivicay package insert. ViiV Healthcare, Research Triangle Park, NC."},{"key":"e_1_3_3_13_2","unstructured":"ViiV Healthcare. 2020. ViiV Healthcare announces US FDA approval of the first-ever dispersible tablet formulation of dolutegravir Tivicay PD a once-daily treatment for children living with HIV. ViiV Healthcare London UK."},{"key":"e_1_3_3_14_2","unstructured":"ViiV Healthcare. 2021. ViiV Healthcare receives EU Marketing Authorisation for the first-ever dispersible-tablet formulation of dolutegravir Tivicay a treatment for children living with HIV in Europe. ViiV Healthcare London UK."},{"key":"e_1_3_3_15_2","unstructured":"ViiV Healthcare. 2021. Tivicay summary of product characteristics. ViiV Healthcare BV Amersfoort Netherlands."},{"key":"e_1_3_3_16_2","unstructured":"Vavro C Ruel T Wiznia A Alvero C Popson S Hazra R Townley E Buchanan A Stewart E Palumbo P. 2020. Emergence of resistance in HIV-1 integrase following dolutegravir treatment in participants aged 4 weeks to <18 years: results from the IMPAACT 1093 study abstr 26. In Abstr European Meeting on HIV & Hepatitis: Treatment Strategies & Antiviral Drug Resistance 2020."},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/jpids\/piy139"},{"key":"e_1_3_3_18_2","unstructured":"Ruel T Farhad M Alvero C Acosta EP Singh R George K Montanez N Popson S Bartlett M Dayton D Anthony P Buchanan A Brothers C Vavro C Koech L Vhembo T Hazra R Townley E Wiznia A IMPAACT P1093 Team. 2020. Twenty-four week safety tolerability and efficacy of dolutegravir dispersible tablets in children 4 weeks to <6 years old with HIV-1: results from IMPAACT P1093 abstr PEB0293. In Abstr 23rd International AIDS Conference."},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01835-13"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.03353-14"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit696"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1093\/jpids\/piu146"},{"key":"e_1_3_3_23_2","unstructured":"Underwood MR DeAnda F Dorey D Hightower K Wang R Griffith S Horton J. 2015. Resistance post week 48 in ART-experienced integrase inhibitor-naive subjects with dolutegravir (DTG) vs. raltegravir (RAL) in SAILING (ING111762) abstr 6. Abstr 13th European HIV & Hepatitis Workshop."},{"key":"e_1_3_3_24_2","unstructured":"ViiV Healthcare. 2021. Dovato package insert. ViiV Healthcare Research Triangle Park NC."},{"key":"e_1_3_3_25_2","unstructured":"ViiV Healthcare. 2021. Triumeq package insert. ViiV Healthcare Research Triangle Park NC."},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000001993"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000002032"},{"key":"e_1_3_3_28_2","first-page":"111","article-title":"2019 update of the drug resistance mutations in HIV-1","volume":"27","author":"Wensing AM","year":"2019","unstructured":"Wensing AM, Calvez V, Ceccherini-Silberstein F, Charpentier C, G\u00fcnthard HF, Paredes R, Shafer RW, Richman DD. 2019. 2019 update of the drug resistance mutations in HIV-1. Top Antivir Med 27:111\u2013121.","journal-title":"Top Antivir Med"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.06170-11"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1186\/1742-4690-11-7"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.aah5163"},{"key":"e_1_3_3_32_2","unstructured":"Wiznia A Alvero C Fenton T George K Townley E Hazra R Graham B Buchanan A Vavro C Viani R P1093 Team. 2016. IMPAACT 1093: dolutegravir in 6- to 12-year-old HIV-infected children: 48-week results abstr 816. In Abstr Conference on Retroviruses and Opportunistic Infections."},{"key":"e_1_3_3_33_2","unstructured":"Ruel T Acosta EP Singh R Alvero C Fenton T George K Townley E Hazra R Popson S Buchanan AM Brothers C Vavro C Wiznia A IMPAACT P1093 Team. 2018. Pharmacokinetic and 4-week safety\/efficacy of dolutegravir (S\/GSK1349572) dispersible tablets in HIV-infected children aged 4 weeks to <6 years: results from IMPAACT P1093 abstr LBPEB023. In Abstr 12th International AIDS Conference."},{"key":"e_1_3_3_34_2","unstructured":"Ruel T Acosta E Singh R Alvero C George K Popson S Vavro C Hazra R Wiznia A the P1093 Team. 2017. Dolutegravir pharmacokinetics safety and efficacy in HIV+ children 2 to <6 years old abstr 806. In Abstr Conference on Retroviruses and Opportunistic Infections."},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkw256"},{"key":"e_1_3_3_36_2","unstructured":"Schr\u00f6dinger LLC. 2019. Schr\u00f6dinger release 2019\u20133: Maestro version 12.1.013. Schr\u00f6dinger LLC New York NY."},{"key":"e_1_3_3_37_2","unstructured":"Schr\u00f6dinger LLC. 2019. Schr\u00f6dinger release 2019\u20133: MMshare version 4.7.013. Schr\u00f6dinger LLC New York NY."}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01645-21","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01645-21","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T23:40:15Z","timestamp":1645486815000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.01645-21"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,18]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1,18]]}},"alternative-id":["10.1128\/AAC.01645-21"],"URL":"https:\/\/doi.org\/10.1128\/aac.01645-21","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,18]]},"assertion":[{"value":"2021-08-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-10-22","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-01-18","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e01645-21"}}